Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Clinical trial NCT05173987 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05173987
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-03
- Primary completion
- 2027-05-27
- Enrollment
- 280
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.